Biotech Stock Silexion Therapeutics Corp. (NASDAQ: SLXN) Soars on Update and First Quarter Results
· investorideas.com
Silexion Therapeutics (Nasdaq: SLXN) shares surge over 72% on Phase 2/3 SIL204 trial progress for KRAS-driven pancreatic cancer and Q1 2026 results.
Biotech Stock Silexion Therapeutics Corp. (NASDAQ: SLXN) Soars on Update and First Quarter Results
JOIN OUR FREE TELEGRAM SERVER TODAY Real-time stock alerts a...